synthetic peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-14. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Heseltine married Anne Harding Williams in 1962. They have three children: Annabel (born in 1963), Alexandra (born in 1966), and Rupert (born in 1967), as well as nine grandchildren. During the period Heseltine was the MP for Tavistock in Devon (from 1966 to 1974), he became part of a local 'fishing gang' with poet Ted Hughes. His wife was delighted, as an admirer of the poet, but Heseltine himself did not initially know who he was. At the beginning of November 2016, drawing on an interview with Tatler magazine, it was reported that Heseltine had confessed to strangling his mother's Alsatian in 1964, after the animal had drawn blood, which was falsely interpreted as his having killed the dog. A rumour about such an incident had been in circulation since a 1990 article in The Observer and an unauthorised biography. Heseltine later stated that he had, in fact, subdued the animal using its choke collar after it had attacked him. In an interview with the Press Association, Heseltine said the dog was put down the next day at the vet's insistence, because it had become dangerous and a threat to his pregnant wife and elderly mother. In January 2017, Heseltine was convicted of careless driving and fined £5,000, following an incident on 19 June 2016 in which he pulled out into the path of a cyclist, causing serious injuries, including a broken arm and shattered knees, which required plates and pins.
Citrus greening disease (Chinese: 黃龍病; pinyin: huánglóngbìng abbr. HLB) is a disease of citrus trees caused by bacteria of the genus Liberibacter. These microbes are transmitted by two species of bug: the Asian citrus psyllid Diaphorina citri and the African citrus psyllid Trioza erytreae. It has no known cure. It is graft-transmissible. There are three different types of the disease: a heat-tolerant Asian form, and the heat-sensitive African and American forms. It was first described and reported in southern China in 1919. The African variation was first reported in 1937 in South Africa, where it is still widespread. It reached Florida in 2005, and within three years had spread to the majority of citrus farms. The rapid increase in this disease has threatened the citrus industry in the entire US. As of 2009, 33 countries had reported the infection in their citrus crop.
== Education and career == Hong grew up in China and completed her B.A. degree in chemistry from Mount Holyoke College (summa cum laude) in 1992 and a Ph.D. degree from the University of California, Berkeley in 1996. There she worked in the laboratory of Alexander Pines to investigate phospholipid structure and dynamics using variable-angle-spinning NMR. After a one-year postdoctoral stint in the laboratory of Robert G. Griffin at the Massachusetts Institute of Technology, she went to University of Massachusetts Amherst and developed biosynthetic isotopic labeling approaches to advance protein structure determination by ssNMR. She started an assistant professorship at Iowa State University in 1999, became an associate professor in 2002 and full professor in 2004, and held the first John D. Corbett Professorship from 2007 to 2010. In 2014, she returned to the Massachusetts Institute of Technology as a professor of chemistry.
Sources: en.wikipedia.org
=== Intracrines and regenerative Medicine === The discovery of intracrine loops in stem cell regulation has profound implications for regenerative medicine. Because intracrines can establish long-lasting differentiation programs, they offer potential therapeutic targets for tissue regeneration and repair. For example, in cardiac repair, HMGB1 has been shown to enhance the proliferation and differentiation of cardiac stem cells following myocardial infarction, suggesting that modulating intracrine pathways could improve heart regeneration. The ability of certain intracrines to reprogram cells into pluripotent-like states also opens new avenues for regenerative therapies. Oct3/4, Sox2, and Nanog, all of which are involved in maintaining stem cell pluripotency, can potentially be introduced into cells to drive reprogramming without the need for genetic modification. This approach could provide safer and more controlled methods for generating patient-specific stem cells.
Complement 3 (C3) through its interaction with factors B and D (adipsin) generates C3a. In the human body, C3a is rapidly cleaved by carboxypeptidase B or carbxyopeptidase N, that remove the carboxyl-terminal arginine to generate C3adesArg. Thus, most of plasmatic C3a is present in C3adesArg form. C3adesArg is more commonly named ASP or acylation-stimulating-protein due to its marked stimulating action on triacylglycerol synthesis in human adipocytes and skin fibroblasts. ASP is also known for its augmentation of glucose transport and inhibiting action on hormone-sensitive lipase. Because of these actions, it is linked to the pathogenesis of obesity, having been demonstrated to be present at increased levels in patients with obesity, diabetes mellitus type 2 and coronary artery disease. ASP lis a ligand for C5L2, a G-protein-coupled receptor. The view of C3a/C3adesArg as an acylation stimulating activity is not universally accepted. The evidence is discussed in a recent review.
Levomethadone, sold under the brand name L-Polamidon among others, is a synthetic opioid analgesic and antitussive which is marketed in Europe and is used for pain management and in opioid maintenance therapy. In addition to being used as a pharmaceutical drug itself, levomethadone is also the main therapeutic component of methadone, which is a racemic mixture of levomethadone (R-methadone) and dextromethadone (S-methadone). Levomethadone is used for narcotic maintenance in place of, or in some cases alongside as an alternative, to racemic methadone, owing to concern that the cardiotoxic and QT-prolonging action of racemic methadone might be primarily caused by dextromethadone.
=== LFA-1 and LFA-3–based therapeutics for autoimmune disease === Although Springer made the first antibodies to LFA-1 and LFA-3, he did not patent them. An antibody isolated by Hildreth and McMichael was licensed to Genentech, which was humanized and approved by the FDA in 2003 for moderate to severe psoriasis as Raptiva. Its generic name efalizumab simulate the letters F and L in LFA-1. Springer and lab member Mike Dustin collaborated with Barbara Wallner at Biogen to clone the cDNA for LFA-3. The LFA-3 ectodomain, which contains one immunoglobulin-like domain, was fused to the Fc domain of IgG to create Amevive. Amevive was approved for moderate to severe psoriasis in 2003. Its generic name, alefacept, is a homophone of LFA plus "cept" from receptor. Royalties paid by Biogen to Dana Farber Cancer Institute were equally shared by Dustin and Springer.
Sources: en.wikipedia.org
Synthetic biology generally falls under existing regulations for GMOs and biotechnology in general, and any regulations that exist for downstream commercial products, although there are generally no regulations in any jurisdiction that are specific to synthetic biology.
== Controversy on acidity == Recent research has challenged these proposed ranges, finding that healthy human skin naturally tends to return to acidity levels below 5.0 when left untouched by skincare products or water for extended periods. An ideal pH value of 4.7 has been identified, with some individuals showing levels as low as 4.3. Subjects with a skin pH below 5.0 exhibited significantly less scaling, higher hydration levels, and better skin flora presence compared to those with higher pH levels, suggesting better overall skin condition. The acidic surface pH is crucial for the growth conditions of resident skin microbiota, which play a vital role in maintaining skin health. Human skin and its microbiota have a mutually beneficial symbiotic relationship, with the skin providing an optimal environment for resident microbiota while the microbiota help reinforce the skin's immunity by preventing colonization by harmful pathogens and contributing to skin acidification. Skin care products that lower skin pH to 4.0–4.5 help maintain resident microbiota on the skin, whereas alkaline personal care products promote their dispersal.
== Safety == In 2023, the European Food Safety Authority reassessed the safety of erythritol and lowered the recommended daily intake limit to 0.5 grams per kg body weight, which equates to 35 g for an average adult (70 kg). The lower limit was set to "safeguard against its laxative effect and to mitigate against long-term effects, such as electrolyte imbalance arising from prolonged exposure to erythritol-induced diarrhea." Previously, in 2015, scientists assessed doses for erythritol where symptoms of mild gastrointestinal upset occurred, such as nausea, excess flatus, abdominal bloating or pain, and stool frequency. At a content of 1.6% in beverages, it was not considered to have a laxative effect. The upper limit of tolerance was 0.78 and 0.71 g/kg body weight in adults and children respectively. In the United States, erythritol is among several sugar alcohols that are generally recognized as safe (GRAS) for food manufacturing.
=== Infant deficiency === Comparative studies carried out in lactating mothers indicate a mean value of vitamin D content in the breast milk of 45 IU/liter. This vitamin D content is too low to meet the vitamin D requirement of 400 IU/day recommended by several government organizations ("...as breast milk is not a meaningful source of vitamin D."). The same government organizations recommend that lactating women consume 600 IU/day, but this is insufficient to raise breast milk content to deliver recommended intake. There is evidence that breast milk content can be increased, but because the transfer of the vitamin from the lactating mother's serum to milk is inefficient, this requires that she consume a dietary supplement above the government-set safe upper limit of 4,000 IU/day. Given the shortfall, there are recommendations that breast-fed infants be fed a vitamin D dietary supplement of 400 IU/day during the first year of life. If not breastfeeding, infant formulas are designed to deliver 400 IU/day for an infant consuming a liter of formula per day – a normal volume for a full-term infant after the first month.
Sierra View Medical Center is a 167-bed, full-service acute care hospital located in Porterville, California. Founded in 1958, the hospital serves the Southern Sequoia region of California's Central Valley. Services include cancer care, an intensive-care unit and respiratory care. The hospital is a part of the Sierra View Local Healthcare District. It offers a wide range of health care services featuring state of the art technologies including Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). The hospital is also home to the Roger S. Good Cancer Treatment Center, which hosts clinical trials of the University of California Los Angeles in oncology. In July 2007, the hospital opened a 32-station outpatient Dialysis Center. The hospital's Wound Healing Center is managed by Healogics. Sierra View Medical Center was awarded the Joint Commission's Gold Seal of Approval for Primary Stroke Centers in 2021, demonstrating compliance with high standards in quality improvement for patient outcomes. The hospital also received the organization's Pioneers in Quality award in 2017. Sierra View Medical Center received the Get With The Guidelines - Stroke GOLD PLUS with Target: Type 2 Diabetes Honor Roll from the American Heart Association. It is also the only hospital in Tulare County to be designated "Baby Friendly" following a World Health Organization and UNICEF-supported initiative aimed at promoting breastfeeding. The Wound Healing Center was awarded the Healogics Robert A. Warriner III Center of Excellence in 2018.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.